IPA is hosting a seminar on June 29, 2005 at our offices in Ashburn, Virginia to outline our vision for innovative research to support the pharmaceutical industry. The seminar is open to all pharmaceutical firms and will include presentations by IPA and pharmaceutical companies as well as facilitated breakout sessions where attendees will focus on topics of mutual interest.
A key goal for the seminar is to plan new research to quantify best practices for the capital project phases that differentiate pharmaceutical companies from other industries; for example: 1) Commercializing Products Through Better Integration with R&D and Business and 2) Improving Financial Returns through Better Regulatory Coordination.
Your participation will provide us with valuable insight regarding your research needs as we develop topics and work through logistics for executing the research plan. Through your contribution, IPA’s demonstrated methodology will be applied to the questions and problems that matter most to you. Results of the research will be presented at IPA’s annual Industry Benchmarking Consortium (IBC) meeting.
Based on current interest, we expect attendance from 15 major pharmaceutical companies at the June 29 meeting. The expected outcome is a decision by each attending company regarding participation in the 3-year research program developed as part of the seminar.
Other than travel, there is no cost to participate in the seminar, as your contribution is valuable. For attendees arriving the day before, IPA will provide a reception and dinner on the evening of June 28.
|
Pharmaceutical Capital Effectiveness:
Research Vision 2005-2008
IPA Seminar Agenda
June 29, 2005
|
| 8:00 – 8:15 |
Introductions & Meeting Objectives – Allison Aschman, IPA Manager for Pharmaceuticals |
| 8:15 – 8:30 |
IPA’s Role in the Pharmaceutical Industry – Dean Findley, IPA Regional Director for North America. Summarizes the history of IPA’s work in the pharmaceutical industry and highlights what distinguishes IPA from other organizations. |
| 8:30 – 9:15 |
J&J’s Benchmarking Experience, Overview and Implementation of a Gated Work Process – Art Goehry, Director, Project Management, Johnson & Johnson. J&J will provide an overview of their capital project system gated work process, implementation, and training. J&J will discuss how they used IPA research to support their efforts, expected improvements in capital project execution, and plans for new opportunities. |
| 9:15 – 9:30 |
Break |
| 9:30 – 10:15 |
Merck’s Experience in Capital Project Delivery and Overview of Future Interests – Tim Phelan, Associate Director, Strategic Planning & Operational Excellence, Merck. Merck’s history in applying a gated work process for capital projects will be summarized. Future project system improvement opportunities include improved integration with R&D, business, and regulators. Merck’s plans for using metrics to document best practices and improvement will be outlined. |
| 10:15 – 10:30 |
Break |
| 10:30 – 11:00 |
IPA’s Vision for the Pharmaceutical Industry Three-Year Research Plan – Edward Merrow, IPA President. This presentation will outline IPA’s goals for the pharmaceutical industry research program, including a discussion of IPA’s approach to capital project research. The Industry Benchmarking Consortium (IBC) meeting, hosted annually by IPA to present metrics and research studies, will also be discussed. The results of the pharmaceutical industry studies will be delivered at the IBC meeting. |
| 11:00 – 12:00 |
Facilitated Discussion of the Research Plan (1) – Allison Aschman. We will map out the topics of interest to the industry. IPA will present the proposed 3-year outline and potential topics. Through facilitated discussion, we will further define the research plan. We will present our vision, developed in concert with our current pharmaceutical clients, and seek your input on the issues critical to your company. |
| 12:00 – 1:30 |
Lunch and Networking Opportunity |
| 1:30 – 2:30 |
Facilitated Discussion of the Research Plan (2) – Allison Aschman. We will finalize the structure of the research plan and discuss the logistics so that all the participants have a clear understanding of all commitments, expectations, etc. |
| 2:30 – 3:00 |
Commissioning and Qualification Challenges: Lessons Learned From Completed Projects - Allison Aschman. IPA recently completed a study to identify and quantify Best Practices for the C&Q phases of pharmaceutical projects. This presentation will summarize the results and illustrate how IPA research helps companies navigate challenging issues. Discussion of this study will also clarify logistics and expectations around participation in IPA’s pharmaceuticals research consortium. |
| 3:00 – 3:30 |
Break and Informal Discussion |
| 3:30 – 4:15 |
Facilitated Discussion – Lessons Learned in Improving Capital Project Delivery Systems, David Gottschlich, IPA Chief Scientist. Group discussion addressing specific approaches for implementing improvements. This session will start with summary presentation of IPA’s research into Best Practices and pitfalls in implementing project system improvements, leading into the main discussion of participants’ experiences. |
| 4:15 – 4:30 |
Wrap-Up |